CONMED Corporation (CNMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: while there is a slight increase in EPS and cash flow, there are concerns about declining gross margins, a significant drop in GAAP net income, and management's reluctance to provide future guidance. The leverage ratio improvement and AirSeal's growth are positives, but the orthopedic backlog and tariff impacts are negatives. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
Key Financial Performance
Total Sales Approximately $338 million, representing 6.7% growth year-over-year as reported and 6.3% growth in constant currency. Growth was led by general surgery (6.9% globally on a constant currency basis) and orthopedics (5.3% globally on a constant currency basis).
Adjusted Net Income $33.4 million, up 2.2% year-over-year, excluding special items that affected comparability.
Adjusted Diluted Earnings Per Share $1.08, an increase of 2.9% compared to the prior year quarter.
Adjusted Gross Margin 56.1%, reflecting a 40 basis point decline compared to Q3 of 2024 due to high manufacturing variances and 20 basis points of headwind from new tariffs.
Research and Development Expense 4.1% of sales, 20 basis points lower than the prior year quarter.
Adjusted SG&A Expenses 37.3% of sales, 10 basis points higher than the prior year.
Adjusted Interest Expense $6.3 million in the third quarter.
Adjusted Effective Tax Rate 25.5% in Q3.
GAAP Net Income $2.9 million compared to $49.0 million in 2024.
GAAP Earnings Per Diluted Share $0.09 this quarter compared to $1.57 a year ago.
Cash Balance $38.9 million as of September 30, compared to $33.9 million at June 30.
Accounts Receivable Days 60 days as of September 30, down from 62 days at the end of Q2.
Inventory Days 191 days as of September 30, down from 212 days at the end of June.
Long-term Debt $853.0 million as of September 30, versus $881.1 million as of June 30.
Leverage Ratio 3.0x as of September 30, reaching the milestone slightly ahead of expectations.
Cash Flow from Operations $53.7 million in the quarter, compared to $51.2 million in the third quarter of 2024.
Capital Expenditures $5.2 million in the third quarter, compared to $3.4 million a year ago.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BioBrace: BioBrace continues to be a cornerstone of our sports medicine strategy. Quarter 3 growth was driven by expanding clinical adoption and strong surgeon engagement. BioBrace is now used across 70-plus distinct procedures from rotator cuff and ACL repairs to Achilles and gluteus medius reconstructions, underscoring its versatility and clinical relevance.
Foot and Ankle franchise: Continued opportunity in this clinical area with a focus on driving growth and delivering strong economic returns through expanded adoption and portfolio innovation.
Buffalo Filter: Sustained momentum driven by expanding legislative mandates, heightened awareness of surgical smoke risks, and deeper integration to hospital protocols.
AirSeal: Remains a foundational pillar of the general surgery portfolio. Clinical benefits include reduced postoperative pain, shorter length of stay, and improved outcomes. AirSeal attachment rates are within expectations, and there is potential for accelerated global growth, particularly in regions with increasing Xi placements.
Geographic Sales Performance: U.S. sales increased 5.9% year-over-year, while international sales grew 6.8%. General surgery sales grew 6.9% globally, with U.S. growth at 6.0% and international growth at 9.2%. Orthopedic sales grew 5.3% globally, with U.S. growth at 5.5% and international growth at 5.2%.
Adjusted Gross Margin: 56.1% in Q3, ahead of projections due to positive sales mix, though down 40 basis points year-over-year due to high manufacturing variances and new tariffs.
Leverage Ratio: Reduced to 3.0x as of September 30, slightly ahead of expectations, providing additional flexibility for share repurchases.
Cash Flow: Cash flow from operations was $53.7 million in Q3, compared to $51.2 million in the prior year. Capital expenditures were $5.2 million, up from $3.4 million a year ago.
Portfolio Review: A comprehensive strategic review is underway to sharpen focus, improve margin profile, and position for long-term growth. Early findings highlight strongest growth opportunities in core markets like minimally invasive robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.
Capital Allocation: Transitioning from legacy dividend policy to a $150 million share repurchase program, with at least $25 million in annual repurchases expected. This change enhances financial flexibility and aligns with long-term shareholder value creation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs Impact: The company faced a 20 basis point headwind from new tariffs, which negatively impacted gross margins in Q3 2025.
Manufacturing Variances: High manufacturing variances in Q1 2025 led to a 40 basis point decline in gross margin for Q3 2025.
Debt Levels: Long-term debt remains high at $853 million, though it has decreased slightly from the previous quarter.
Dividend Suspension: The company has suspended its legacy dividend policy, which may impact investor sentiment, although it plans to prioritize share repurchases.
Portfolio Review Uncertainty: The ongoing strategic review of the portfolio and operations introduces uncertainty regarding future product focus and investments.
Economic Pressures: The company faces economic pressures, including the need to balance investments in innovation with maintaining profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q4 2025: Revenue is expected to be between $363 million and $370 million, representing mid-single-digit constant currency growth with about 100 basis points of tailwind from currency.
Full Year 2025 Revenue Guidance: Reported revenue is projected to be in the range of $1.365 billion to $1.372 billion, with FX expected to be neutral for the year.
Adjusted Gross Margin for Q4 2025: Expected to be in the mid-55% range, inclusive of about 150 basis points of headwind from new tariffs.
Adjusted EPS Guidance for Q4 2025: Expected to be between $1.30 and $1.35.
Full Year 2025 Adjusted EPS Guidance: Projected to be in the range of $4.48 to $4.53.
Portfolio Review Insights: The company is focusing on core markets such as minimally invasive robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. Investments will prioritize platforms like AirSeal, Buffalo Filter, and BioBrace to drive growth and profitability.
Capital Allocation Changes: The company is transitioning from a legacy dividend policy to a $150 million share repurchase program, with at least $25 million in annual share repurchases expected.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Legacy Dividend Policy: The company has historically returned approximately $25 million annually through dividends.
Dividend Suspension: The company announced the suspension of its dividend policy to prioritize share repurchases.
Share Repurchase Program: The Board has authorized a new $150 million share repurchase program.
Annual Share Repurchase Expectation: The company plans to repurchase at least $25 million worth of shares annually going forward.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What drove the shift in capital allocation strategy and should we expect changes in M&A or debt pay down?
A:The shift was driven by reaching the 3.0 leverage target earlier than expected, aligning with peer med device companies, and prioritizing share repurchases over dividends. No other changes in M&A or debt pay down are expected.
Q:What are the early thoughts on 2026 regarding supply and demand?
A:Management avoided providing specifics, stating they will guide 2026 at the appropriate time and had no additional details to share.
Q:Was there any incremental tariff headwind versus expectations?
A:No, the tariff impact has been consistent with prior forecasts. Tariffs from Q1 and Q2 of 2025 are being recognized in Q4 of 2025, as projected.
Q:What prevents DV5's insufflator utilization from reaching 100% and where does AirSeal fit in?
A:Utilization is limited by hospitals' commitment to a set number of procedures with DV5. AirSeal provides clinical benefits like shorter stays and pain reduction, and its adoption is growing post-commitment volumes.
Q:What is the adoption rate of Xi systems in ASCs and international markets?
A:Xi systems benefit from AirSeal's clinical advantages, such as shorter stays and pain reduction. Adoption is expected to grow in ASCs and international markets due to these benefits.
Q:What initiatives strengthened the supply chain in Q3 and how will they be maintained through 2026?
A:Supply chain improvements included record manufacturing volumes, reduction in critical SKUs, and enhancements in procurement, planning, and production. Progress is ongoing, with further improvements expected in Q4.
Q:What is the progress in U.S. AirSeal non-robotic laparoscopic opportunities and international robotic attachments?
A:AirSeal is gaining traction in non-robotic laparoscopic procedures in the U.S. and is being used with non-DV5 robotic systems internationally, where its clinical benefits are recognized.
Q:What are the latest thoughts on orthopedic share loss and BioBrace's growth?
A:Orthopedic share recovery will take time post-supply chain resolution. BioBrace's growth is driven by its clinical benefits and expanded indications, with procedures increasing from 52 to 70+.
Q:What trends are seen in the capital environment and expectations for the next 12 months?
A:The capital environment remains healthy, with hospitals investing in equipment that improves outcomes and throughput. This trend is expected to continue as interest rates decrease.
Q:How do operational improvements support margin expansion in 2026?
A:Operational improvements are expected to save tens of millions of dollars, but new tariffs may offset some gains. Specific 2026 guidance will be provided in the Q4 call.
Q:What drove the improvement in orthopedics growth in Q3?
A:Growth was driven by BioBrace's success and improved service levels due to reduced back orders. However, management emphasized that operational progress is ongoing.
Q:What is the timeline for resolving the orthopedic backlog?
A:The backlog resolution is in the second half of progress, possibly in the sixth or seventh inning. Full resolution will take additional quarters.
Q:Review of Unclear Management Responses
A:Management avoided providing specifics on 2026 guidance, stating they will address it at the appropriate time. Additionally, they did not provide a clear timeline for orthopedic backlog resolution, only indicating they are in the second half of progress.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASCs opportunity
AirSeal advantage
AirSeal momentum
Ankle driver
Ankle franchise
Ankle procedure
BioBrace cornerstone
BioBrace momentum
CEO decade
CONMED outcome
CONMED review
CONMED set
CONMED term
CONMED today
DV adoption
Mr afternoon
Officer review
Pat President
States ASCs
Today dividend
ability line
adoption attachment
adoption portfolio
adoption surgeon
advantage priority
allocation framework
announcement Pat
commitment
health care
orthopedics
outcome patient
platform
share repurchase
surgery portfolio
term return
CNMD Transcript
CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call presents a mixed picture: improved profitability, positive revenue growth guidance, and margin improvements are balanced by concerns over increased interest expenses and supply chain issues. The Q&A section reveals management's vague responses on key metrics, which could create uncertainty. The company's market cap suggests moderate price sensitivity. Overall, despite some positive aspects, the lack of clarity on critical issues and potential financial headwinds lead to a neutral prediction, with stock price expected to remain stable within a -2% to 2% range over the next two weeks.
CONMED Corporation (CNMD) Q4 2025 Earnings Call Transcript
Positive1-28
The earnings call highlights strong financial performance with EPS growth and improved cash flow. The transition to a share repurchase program and strategic focus on high-margin platforms are positive indicators. The Q&A reveals confidence in growth opportunities and strategic focus, despite minor portfolio adjustments. The positive sentiment is reinforced by strong OUS growth and a balanced approach to M&A and R&D investments. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
CONMED Corporation (CNMD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed picture: while there is a slight increase in EPS and cash flow, there are concerns about declining gross margins, a significant drop in GAAP net income, and management's reluctance to provide future guidance. The leverage ratio improvement and AirSeal's growth are positives, but the orthopedic backlog and tariff impacts are negatives. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
CNMD Slides
CNMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
